Back to News
Nov 11, 2025 4:00 PM

Analyst Sees Strong Medtronic Momentum Through 2026 With Buy Rating Intact

Medical devices giant Medtronic Plc (NYSE:MDT) is scheduled to report its second-quarter fiscal year 2026 results on Tuesday, November 18.

According to data from Benzinga Pro, analysts estimate adjusted earnings of $1.315 per share and sales of $8.865 billion.

Bank of America (BofA) Securities expects Medtronic to post over 5% revenue growth in fiscal Q2, with momentum accelerating through the second half of FY25 and into 2026.

BofA maintains a Buy rating.

Analyst Travis Steed noted Medtronic likely needs to exceed 5% growth in the second quarter to justify a full-year guidance raise. He pointed out that the broader medtech space, from TAVR to Spine, ...